Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone - Janssen

Drug Profile

Risperidone - Janssen

Alternative Names: JNJ 410397 AAA; R 64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen L.P.
  • Developer Alkermes; Janssen; Janssen L.P.; Janssen Pharmaceutical KK; Janssen-Cilag; Xian-Janssen
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
  • No development reported Anxiety disorders; Major depressive disorder; Obsessive-compulsive disorders; Substance-related disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 28 Feb 2018 Xian Janssen withdraws a phase I bioequivalence trial prior to enrolment in healthy volunteers in China (NCT03220867)
  • 11 Dec 2017 Xian Janssen initiates enrolment in a phase I bioequivalence trial in healthy volunteers in China (NCT03220867)
  • 14 Jul 2017 Xian-Janssen plans a phase I bioequivalence trial in Healthy volunteers in China (PO) (NCT03220867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top